Online Program Home
My Program

Keyword Search

Legend:
CC = Vancouver Convention Centre   F = Fairmont Waterfront Vancouver
* = applied session       ! = JSM meeting theme

Keyword Search Criteria: Dose-Finding returned 15 record(s)
Sunday, 07/29/2018
Optimal Dose Selection Considering Both Toxicity and Activity Data; Plateau Detection for Molecularly Targeted Agents
Maria Athina Altzerinakou, Inserm; Xavier Paoletti, Gustave Roussy
2:20 PM

MCP-Mod Based Quantitative Techniques for Decision Making Process in Phase II Dose-Finding Clinical Trials
Na Cai, Astellas; Annie Wang, Astellas Pharma; Michael Smith, Astellas
5:20 PM

Tuesday, 07/31/2018
Non-Inferiority Margins in Superiority/Non-Inferiority Seamless Clinical Trials
Ellen Gurary, Boston University; Joe Massaro, Boston University


Bridging Information Between Dose-Response Curves Across Populations in Early Phase Clinical Trials
Moreno Ursino, Inserm DR PA 6


Bridging Information Between Dose-Response Curves Across Populations in Early Phase Clinical Trials
Moreno Ursino, Inserm DR PA 6
8:45 AM

A Case Study of a Bayesian Adaptive Dose-Finding Phase 2 Trial Design Using Go/No-Go Criteria and Adaptive Randomization
Ye Ting Du; James Bolognese, Cytel Inc
9:35 AM

Reversals in Early Phase Dose Finding Trials
Bethany Horton, University of Virginia; John O'Quigley, Universit'e Pierre et Marie Curie, ; Mark Conaway, University of Virginia
10:35 AM

Statistical Graphics in Drug Development: Dose-Finding to Dossier Submission
Suddhasatta Acharyya, Novartis pharmaceuticals corporation
11:50 AM

AAA: Triple-Adaptive Bayesian Designs for the Identification of Optimal Dose Combinations in Dual-Agent Dose-Finding Trials
Jiaying Lyu, University of Chicago; Fudan University; Yuan Ji, NorthShore Univ. HealthSystem / The University of Chicago
11:55 AM

Wednesday, 08/01/2018
Bayesian Adaptive Design of Phase 2 Dose-Finding Study
Tanya Granston, CTI BioPharma Corp.; Huafeng Zhou, CTI BioPharma Corp.; Lixia Wang, CTI BioPharma Corp.


Bayesian Adaptive Design of Phase 2 Dose-Finding Study
Tanya Granston, CTI BioPharma Corp.; Huafeng Zhou, CTI BioPharma Corp.; Lixia Wang, CTI BioPharma Corp.
9:45 AM

Improving Dose-Finding for Early Oncology Trials with Monotherapy and Combination Therapy
Zhen Zeng, Merck & Co.; Meihua Wang, Merck & Co.; Victoria Plamadeala Johnson, Merck & Co.; Cong Chen, Merck & Co.
11:15 AM

AAA: Triple-Adaptive Bayesian Designs for the Identification of Optimal Dose Combinations in Dual-Agent Dose-Finding Trials
Yuan Ji, NorthShore Univ. HealthSystem / The University of Chicago; Jiaying Lyu, Fudan Universtiy
11:35 AM

Dependencies in Binary Regression Data Generated by Informed Sequential Dose Allocation
Nancy Flournoy, University of Missouri; Assaf Oron, Instutue for Disease Modeling
2:25 PM

Thursday, 08/02/2018
Target Toxicity Design for Phase 1 Dose-Finding: a Safe and Reliable Method
Bob Zhong, Johnson and Johnson; Wenchuan Guo, University of California Riverside
9:50 AM